Abstract
Mental illness affects a quarter of the US population. Recently, it has been shown that new, carbohydrate-based drugs hold promise in the treatment of central nervous system (CNS) disorders. A variety of ways in which drugs of this sort may reduce the symptoms of epilepsy, depression and other affective disorders have been proposed, including: targeting the immune system, disrupting glycolysis, acting at different sites in the hypothalamic-pituitary-adrenal (HPA) axis, and targeting specific biochemical pathways such as the inositol pathway. In the present review, the structureactivity relationships (SARs) of a wide variety of CNS-active carbohydrates are presented.
Keywords: Glycolysis, topiramate, saponins, steroidal glycosides, capsular saccharides
Current Topics in Medicinal Chemistry
Title: Carbohydrate-Based Drugs in the Treatment of Epilepsy, Depression and Other Affective Disorders
Volume: 8 Issue: 2
Author(s): Cecilia H. Marzabadi and Ian Jamie Talisman
Affiliation:
Keywords: Glycolysis, topiramate, saponins, steroidal glycosides, capsular saccharides
Abstract: Mental illness affects a quarter of the US population. Recently, it has been shown that new, carbohydrate-based drugs hold promise in the treatment of central nervous system (CNS) disorders. A variety of ways in which drugs of this sort may reduce the symptoms of epilepsy, depression and other affective disorders have been proposed, including: targeting the immune system, disrupting glycolysis, acting at different sites in the hypothalamic-pituitary-adrenal (HPA) axis, and targeting specific biochemical pathways such as the inositol pathway. In the present review, the structureactivity relationships (SARs) of a wide variety of CNS-active carbohydrates are presented.
Export Options
About this article
Cite this article as:
Marzabadi H. Cecilia and Talisman Jamie Ian, Carbohydrate-Based Drugs in the Treatment of Epilepsy, Depression and Other Affective Disorders, Current Topics in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/156802608783378846
DOI https://dx.doi.org/10.2174/156802608783378846 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Standardization Using Analytical Techniques (UV, NMR, FTIR, HPLC, Mass) and Pharmacognostic Evaluation of the Roots of <i>Selinum vaginatum</i>: A Rare Himalayan Plant of the Rohtang Region
Current Biotechnology Potential for Discovery of Neuroprotective Factors in Serum and Tissue from Hibernating Species
Mini-Reviews in Medicinal Chemistry Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in Schizophrenia
Current Pharmaceutical Design Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Natural Products as a Source of CNS-Active Agents
Mini-Reviews in Organic Chemistry Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Neuropharmacology Potential Phytotherapeutic Approaches for the Treatment of Alzheimer’s Disease: An Overview
Current Traditional Medicine Recent Knowledge on Medicinal Plants as Source of Cholinesterase Inhibitors for the Treatment of Dementia
Mini-Reviews in Medicinal Chemistry The Validity of Mobile Applications to Facilitate Patient Care Provided to Cancer Patients: Opportunities and Limitations
Recent Patents on Anti-Cancer Drug Discovery Nicotine, Lung and Cancer
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology Pharmacological Investigation and Unraveling Mechanism of Action of Jasminum sambac Flowers for Predicated Treatment of Alzheimer’s Disease
Current Nutrition & Food Science (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology